Prevention of Transition From Incipient to Overt Nephropathy With Telmisartan in Patients With Type 2 Diabetes

Diabetes Care - Tập 30 Số 6 - Trang 1577-1578 - 2007
Hirofumi Makino1, Masakazu Haneda2, Tetsuya Babazono3, Tatsumi Moriya4, Sadayoshi Ito5, Yasuhiko Iwamoto6, Ryuzo Kawamori7, Masahiro Takeuchi8, Shigehiro Katayama9
1Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
2Department of Medicine, Division of Metabolism and Biosystemic Science, Asahikawa Medical College, Hokkaido, Japan
3Division of Nephrology and Hypertension, Diabetes Center, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan
4Department of Endocrinology, Diabetes and Metabolism, Kitasato University School of Medicine, Kanagawa, Japan
5Division of Nephrology, Tohoku University Graduate Medical School, Miyagi, Japan
6Department of Medicine, Diabetes Center, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan
7Department of Medicine, Medical School, Juntendo University, Tokyo, Japan
8Division of Biostatistics, School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan
9Division of Endocrinology and Diabetes, Department of Medicine, Saitama Medical School, Saitama, Japan

Tóm tắt

Từ khóa


Tài liệu tham khảo

Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, for the RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861–869, 2001

Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, for the Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851–860, 2001

Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P, for the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870–878, 2001

Hollenberg NK: Higher incidence of diabetic nephropathy in type 2 than in type 1 diabetes in early-onset diabetes in Japan. Curr Hypertens Rep 3:177, 2001

US Renal Data System: USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Available from http://www.usrds.org/adr_2005.htm

Nakai S, Shinzato T, Nagura Y, Masakane I, Kitaoka T, Shinoda T, Yamazaki C, Sakai R, Ohmori H, Morita O, Iseki K, Kikuchi K, Kubo K, Suzuki K, Tabei K, Fushimi K, Miwa N, Wada A, Yanai M, Akiba T: Patient Registration Committee, Japanese Society for Dialysis Therapy, Tokyo: an overview of regular dialysis treatment in Japan (as of December 31, 2001). Ther Apher Dial 8:3–32, 2004

Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, Kawamori R, Takeuchi M, Katayama S, for the Incipient to Overt; Angiotensin II–Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy Study Group: The telmisartan renoprotective study from incipient nephropathy to overt nephropathy: rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker, telmisartan, investigation on type 2 diabetic nephropathy (INNOVATION) study. J Int Med Res 33:677–686, 2005

Ruggenenti P, Schieppati A, Remuzzi G: Progression, remission, regression of chronic renal diseases. Lancet 357:1601–1608, 2001

Thông tin
Thông tin xuất bản

Diabetes Care

Tập 30 Số 6

1577-1578

Thông tin tác giả